Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update
02 août 2018 07h30 HE
|
Adaptimmune Therapeutics plc
- Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells - - NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets - -...
Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018
26 juil. 2018 13h18 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, July 26, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for...
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
24 juil. 2018 07h30 HE
|
Adaptimmune Therapeutics plc
LONDON and OXFORD, United Kingdom, July 24, 2018 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced...
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
18 juil. 2018 07h29 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, July 18, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of...
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
11 juin 2018 07h30 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the...
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
04 juin 2018 07h30 HE
|
Adaptimmune Therapeutics plc
- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts - - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD,...
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
04 juin 2018 07h30 HE
|
Adaptimmune Therapeutics plc
- No evidence of off-target toxicity at 100 million cells for second wholly owned asset - - Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study...
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
02 juin 2018 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the...
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
16 mai 2018 17h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing...
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
09 mai 2018 07h30 HE
|
Adaptimmune Therapeutics plc
- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO - - Guidance confirmed, funded...